吉西他滨与表柔比星对中高危非浸润性膀胱尿路上皮癌的疗效观察  

Gemcitabine and Epirubicin in the Treatment of Moderate and High-risk Non-invasive Badder Urothelial Carcinoma

作　　者：刘彦军[1] 景治安[1] 毛长青[1] 李纪华[1] 胡和平[1] LIU Yanjun;JING Zhian;MAO Changqing(The First People's Hospital of Zhengzhou,Zhengzhou,450004)

机构地区：[1]河南省郑州市第一人民医院,450004

出　　处：《实用癌症杂志》2018年第12期2059-2061,共3页The Practical Journal of Cancer

摘　　要：目的探讨吉西他滨与表柔比星对中高危非浸润性膀胱尿路上皮癌的疗效。方法将78例中高危非浸润性膀胱尿路上皮癌患者作为研究对象,根据随机分组原则分为观察组(39例)和对照组(39例),观察组患者给予吉西他滨(GEM)治疗,对照组患者给予表柔比星(EPI),分别对两组患者的术后复发、进展情况、不良反应情况进行统计对比。结果观察组患者在用药后,复发率为17. 95%(7/39),进展率为2. 56%(1/39);对照组患者在用药后,复发率为23. 08%(9/39),进展率为5. 13%(2/39),两组间比较无明显差异(P> 0. 05),无统计学意义;同时观察组患者用药后不良反应发生率为23. 08%(9/39);对照组患者用药后不良反应发生率为20. 51%(8/39),两组间比较无明显差异(P>0. 05),无统计学意义。结论针对于中高危非浸润性膀胱尿路上皮癌患者的治疗,吉西他滨以及表柔比星均能够降低患者两年内的复发率,但部分患者会存在不同程度的不良反应,无法改变病情的进展,临床上可推广使用。Objective To discus the efficacy of gemcitabine and epirubicin in the treatment of moderate and high-risk and non invasive bladder urothelial carcinoma.Methods 78 moderate and high-risk non invasive bladder urothelial carcinoma patients were selected as the research object.According to the principle of random grouping,they were divided into observation group(39 cases)and control group(39 cases),patients in the observation group were treated with gemcitabine(GEM)treatment,the control group were treated with epirubicin(EPI).The recurrence,progression and adverse reactions of the two groups were statistically compared.Results The patients in the observation group after treatment,the recurrence rate was 17.95%(7/39),progression rate was 2.56%(1/39),patients in the control group after treatment,the recurrence rate was 23.08%(9/39),progression rate was 5.13%(2/39),there were no significant difference between the two groups(P>0.05),does not have statistical significance.At the same time,patients in the observation group after the treatment,adverse reaction rate was 20.51%(8/39),patients in the control group after treatment,the incidence of adverse reaction was 23.08%(9/39),there were no significant difference between the two groups(P>0.05),with no statistical significance.Conclusion For the treatment in moderate and high-risk non invasive bladder urothelial cancer,gemcitabine and epirubicin were able to reduce the recurrence rate of patients within two years,but some patients have different degrees of adverse reactions,can not change the progress of the disease.It can be widely used in clinic.

关 键 词：吉西他滨 表柔比星 非浸润性膀胱尿路上皮癌 复发率 

分 类 号：R737.14[医药卫生—肿瘤]